Inception – Discovery Stage Research Projects
Return to Grants
Objective
The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. The objective of the Discovery Program is to support exploratory research leading to the discovery of novel stem cell technologies to improve patient care.
DISC 1: The Inception Awards
The Inception Awards Program provides seed funding to support the exploration of transformational ideas that hold the potential to greatly impact the field of human stem cell research, but that require the generation of additional data to be competitive for larger funding opportunities through CIRM or other sources.
Please see the Partnering Opportunity for Discovery Stage Research Projects page for the Inception Program Announcement, application deadline and other details.
To Submit an Application:
- Go to the Grants Management Portal (https://grants.cirm.ca.gov) and log in with your existing CIRM Username and Password. If you do not have a Username, Click on the “New User” link and follow the instructions to create a CIRM Username and password.
- After logging in, select the tab labeled “Open Programs”. Under the section labeled “RFAs and Programs Open for Applications”, click on the applicable link to Start a DISC Grant Application.
- Complete each section of the Application by clicking on the appropriate link and following the posted instructions. Proposal templates can be located and submitted under the “Uploads” section.
- To submit your Application, click on the “Done with Application” button. The “Done with Application” button will be enabled when all of the mandatory sections have been completed. Please note that once this has been selected, you will no longer be able to make changes to your Application.
- To confirm submission of your Application, select the tab labeled “Your Applications” and check the table under the section labeled “Your Submitted Applications”. You will see your Application number and project title listed once the submission process has been completed.
ICOC Approval:
November 30, 2017
Awards
Institution |
Investigator |
Grant Title |
Award Value |
University of California, San Diego | Karl Karl J. Wahlin | An IPSC cell based model of macular degeneration for drug discovery. |
$232,200 |
University of California, Los Angeles | Alireza Moshaverinia | Gingival mesenchymal stem cells as a novel treatment modality for periodontal tissue regeneration |
$194,483 |
Zenobia Therapeutics | Vicki Nienaber | A new phenotypic screening platform that identifies biologically-relevant targets and lead compounds for the treatment of Parkinson’s disease |
$112,500 |
Cedars-Sinai Medical Center | Dmitriy Sheyn | IVD rejuvenation using iPSC-derived notochordal cells |
$241,992 |
Loma Linda University | Dr. David J Baylink | Bone Marrow Targeting of Hematopoietic Stem Cells Engineered to Overexpress 25-OH-VD3 1-α-hydroxylase for Acute Myeloid Leukemia Therapy |
$178,967 |
Palo Alto Veterans Institute for Research | Dr. Ngan F Huang | iPSC-Derived Smooth Muscle Progenitors for Treatment of Abdominal Aortic Aneurysm |
$172,621 |
University of California, Davis | Dr. Alice F Tarantal | Enhanced Branching Morphogenesis and Pluripotent Cell Lineage Differentiation for Pediatric Regenerative Therapies |
$235,800 |
Loma Linda University | Julia J. Unternaehrer-Hamm | Targeting cancer stem cells with nanoparticle RNAi delivery to prevent recurrence and metastasis of ovarian cancer |
$172,870 |
Human BioMolecular Research Institute | Dr. John R Cashman | Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication |
$303,785 |
Stanford University | Professor Hiromitsu Nakauchi | Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion |
$210,906 |
University of California, San Diego | Gerald P Morris | Identification of antigenic neo-epitopes from in vitro reprogrammed human tissue precursors for regenerative therapy |
$193,500 |
University of California, Davis | Alyssa Panitch PhD | Development of treatments to improve healing of ischemic wounds |
$235,099 |
Stanford University | Guillem Pratx | Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET |
$229,227 |
University of California, San Francisco | Semil P Choksi | Generation of human airway stem cells by direct transcriptional reprogramming for disease modeling and regeneration |
$238,408 |
University of California, Irvine | Janet E Baulch | An exosome-based translational strategy to mitigate Alzheimer’s disease neuropathology |
$157,650 |
University of California, San Diego | Dr. Tannishtha Reya | Reprogramming human stem cells for blood cell generation |
$210,060 |
Stanford University | Dr. Helen M Blau | Prodrug innovation to target muscle stem cells and enhance muscle regeneration |
$235,834 |
Sanford Burnham Prebys Medical Discovery Institute | Dr Alessandra Sacco | Generation of expandable, self-renewing muscle stem cells for Duchenne Muscular Dystrophy |
$252,000 |
University of California, San Francisco | Sonja Schrepfer | Hypo-immunogenic cardiac patches for myocardial regeneration |
$235,818 |
University of Southern California | Biju B. Thomas | A Novel Tissue Engineering Technique to Repair Degenerated Retina |
$215,133 |
Children’s Hospital of Los Angeles | Dr. Senta Georgia | Developing a personalized approach to beta cell replacement for patients with a genetic form of diabetes |
$179,995 |
Vitalant Research Institute | Dr. Marcus Oliver Muench | Modulating Liver Sinusoidal Endothelial Cell Permeability to Enhance Engraftment of Endothelial Cell Progenitors for the Treatment of Hemophilia A |
$180,000 |
Stanford University | Jeffrey L Goldberg | Embryonic Stem Cells for Corneal Endothelial Degeneration |
$235,836 |
University of California, Los Angeles | Dr. Owen N Witte M.D. | Identification of stem cell surface markers as potential therapeutic targets for advanced prostate cancer |
$209,160 |
University of California, San Diego | Professor Alysson R Muotri | Reverse transcriptase inhibitors as a novel therapeutic approach for neurological autoimmune disorders |
$210,060 |
University of California, Los Angeles | Dr. April Pyle Ph.D. | Novel Platforms to Enhance In Vivo Delivery of Skeletal Muscle Progenitor Cells from Human Pluripotent Stem Cells |
$230,400 |
University of California, Los Angeles | Dr. Bennett G Novitch Ph.D. | Organoid Modeling of Human Cortical Microcircuits |
$208,916 |
Cedars-Sinai Medical Center | Professor Clive Niels Svendsen | Blood Brain Barrier (BBB)-on-Chip: Development and validation of a novel iPS-based microfluidic model of the human BBB |
$241,992 |
University of California, San Francisco | Dr. Holger F Willenbring | Generation of bile duct-competent transplantable human liver organoids |
$206,460 |
University of California, Los Angeles | Dr. Arjun Deb | Targeting progenitors in scar tissue to reduce chronic scar burden |
$230,400 |
University of California, Berkeley | Dr. Jacob Ellery Corn Ph.D | Genome editing for causation and reversion of MPN-associated mutations in human hematopoietic stem cells |
$235,800 |
Stanford University | Dr. Philip Arden Beachy PhD | Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
University of California, San Diego | Dionicio Siegel | New Methods for the Chemical Expansion of Hematopoietic Stem and Progenitor Cells |
$232,200 |
Stanford University | Dr. Bertha Chen | Autologous iPSC-based therapy for radiation induced bladder injury |
$235,836 |
University of California, Los Angeles | Dr. Thomas Carmichael M.D., Ph.D. | iPS-Interneuron Transplantation for Neural Repair after Stroke |
$229,396 |
University of California, San Diego | Karl Karl J. Wahlin | Microenvironment based optimization of retinal induction using CRISPR-CAS9 reporter pluripotent stem cells as an expandable source of retinal progenitors and photoreceptors. |
$232,200 |
University of California, San Francisco | Andrew Stephen Brack | Examining the efficacy of GDF11 antibody as a rejuvenator of aged human muscle stem cell capacity and muscle repair . |
$180,000 |
Stanford University | Dr. Phillip C Yang | Activation of patient-specific endogenous myocardial repair through the exosomes generated from the hypoxic iPSC-derived cardiomyocytes (iCMs). |
$234,619 |
Cedars-Sinai Medical Center | Linda Cambier | Exosomal Y-RNAs as mediators of bioactivity of cardiac-derived cell therapy |
$181,063 |
| | | Total: $8,364,091.97 |